Vertex Pharmaceuticals Announces Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis

Vertex Pharmaceuticals Incorporated VRTX today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis activity. The 12-week study met its two primary endpoints, defined as a statistically significant improvement in the proportion of people who achieved at least a 20 percent improvement in the signs and symptoms of RA, also known as ACR20, and a statistically significant improvement from baseline in Disease Activity Score 28.